News

Filter

Current filters:

sofosbuvir

1 to 9 of 36 results

Merck’s triple-therapy hepatitis C regimen shows sub-optimal efficacy

Merck’s triple-therapy hepatitis C regimen shows sub-optimal efficacy

11-11-2014

US pharma giant Merck & Co has admitted that interim data from its triple-therapy regimen in hepatitis…

Anti-viralsHCVHepatitis CHepatitis C virusMerck & CoPharmaceuticalResearchsofosbuvirUSA

Janssen’s Olysio/sofosbuvir combination cleared by FDA

Janssen’s Olysio/sofosbuvir combination cleared by FDA

06-11-2014

The Food and Drug Administration has approved US health care giant Johnson & Johnson's Olysio (simeprevir)…

Anti-viralsBiotechnologyJohnson & JohnsonMedivirOlysioRegulationsofosbuvirUSA

Gilead files for Japanese approval of ledipasvir/sofosbuvir for hepatitis C

24-09-2014

Gilead Sciences has submitted a New Drug Application to Japan’s Pharmaceutical and Medical Devices…

Anti-viralsBiotechnologyGilead SciencesJapanledipasvirRegulationsofosbuvir

Achillion soars on positive mid-stage hep C drug combo trial

Achillion soars on positive mid-stage hep C drug combo trial

17-08-2014

US drugmaker Achillion saw its share rocket 18.4% to a 52-week high of $9.99 in pre-market trading on…

ACH-3102AchillionAnti-viralsHepatitis C virusPharmaceuticalResearchsofosbuvirSovaldiUSA

Janssen’s simeprevir for hepatitis C shows good efficacy in Phase II trial

Janssen’s simeprevir for hepatitis C shows good efficacy in Phase II trial

31-07-2014

Some 92% of genotype 1 chronic hepatitis C virus (HCV) adult patients treated with US health care giant…

Anti-viralsGilead SciencesIrelandJanssenPharmaceuticalResearchsimeprevirsofosbuvir

Hepatitis C cured in co-infected HIV patients

Hepatitis C cured in co-infected HIV patients

21-07-2014

A multicenter team of researchers report that in a Phase III clinical trial, a combination drug therapy…

Anti-viralsAntiviralsBiotechnologyGilead SciencesHepatitis CResearchRibavirinsofosbuvirSovaldiThe Johns Hopkins University School of MedicineUSA

Gilead’s ledipasvir/sofosbuvir achieved 100% SVR12 among chronic hepatitis C patients in Japan

Gilead’s ledipasvir/sofosbuvir achieved 100% SVR12 among chronic hepatitis C patients in Japan

16-06-2014

US anti-virals major Gilead Sciences has released strong top-line results from a Phase III clinical trial…

Anti-viralsBiotechnologyGilead SciencesJapanledipasvirRegulationResearchsofosbuvirSovaldi

1 to 9 of 36 results

Back to top